Turner syndrome case report: A multidisciplinary approach by Thiesen, Guilherme et al.
Stomatos, Vol. 21, Nº 40, Jan./Jun. 201512





Maria Perpétua Mota Freitas
ABSTRACT 
Turner syndrome (TS) was fi rst reported in the literature in 1938 by Laurel Thatcher 
Ulrich and Henry Turner. This chromosomal alteration only affects female individuals, who have 
monosomy of the X chromosome. Only one X chromosome is functional, while the other sexual 
chromosome is either absent or abnormal. The main oral characteristics are transverse defi ciency of 
the maxilla, mandibular retrognathism, anterior open bite, cleft palate, premature dental eruption, 
and alterations in the shape, size and thickness of teeth, with an increased number of roots on the 
fi rst and second premolars. The objective of this study was to describe the clinical case of a patient 
with TS undergoing orthodontic treatment, and to emphasize the importance of a multidisciplinary 
approach to patients with TS.
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Relato de caso de síndrome de Turner: uma abordagem 
multidisciplinar 
RESUMO 
A síndrome de Turner (ST) foi relatada pela primeira vez na literatura em 1938, por 
Laurel Thatcher Ulrich e Henry Turner. Esta alteração cromossômica afeta somente pacientes do 
gênero feminino, apresentando uma monossomia do cromossomo X. Isso signifi ca que apenas 
um cromossomo X é funcional, sendo o outro cromossomo sexual inexistente ou anormal. As 
principais características orais observadas são defi ciência transversal da maxila, retrognatismo 
mandibular, mordida aberta anterior, fi ssuras palatinas, erupções dentárias precoces, alterações na 
forma, tamanho e espessura dos dentes, com aumento do número de raízes nos primeiros e segundos 
pré-molares. O objetivo deste trabalho foi descrever um caso clínico de uma paciente com ST 
submetida a tratamento ortodôntico e ressaltar a importância de uma abordagem multidisciplinar 
para estes pacientes. 
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INTRODUCTION
Turner syndrome (TS) was fi rst described by Henry Turner and Laurel Thatcher 
Ulrich in 1938 and is also known as monosomy X or Bonnevie-Ulrich syndrome. It is 
a condition characterized by monosomy of the X chromosome and complete or partial 
absence of the second sex chromosome (1). It only occurs in females and is the most 
common sex chromosome abnormality in females. The estimated prevalence rate is one 
case in 2,500 live female births (2,3).
Women affected by this syndrome develop a specifi c model of skeletal and 
dental features. This includes abnormal craniofacial growth, reduction of the transverse 
dimensions of the maxilla, mandibular sagittal defi ciency, high palatal arch, cleft palate, 
malocclusion, premature dental eruption and changes in tooth shape and size (4-6). The 
posterior cranial base is shortened, and the angle of the base of the skull is fl attened, 
leading to a retrognathic position of the mandible. The result is a small and wide mandible 
combined with a narrow maxillary arch (4). These deviations usually correspond to Angle 
Class II malocclusion, anterior open bite, and posterior crossbite (7). 
These patients have dentition characterized by premature dental development, 
although the sequence of tooth eruption does not differ from the general population. By 
means of radiography, it is possible to observe anomalies of root morphology, such as 
length reduction and abnormal shape. The most frequently observed radiographic changes 
are two roots on the mandibular fi rst and second premolars, with complete development of 
mesial and distal roots. There are also cases of agenesis of incisors, canines and premolars 
reported in the literature (5).
These features can lead to disorders of dental occlusion and this study reports on the 
clinical case of a patient with TS and the orthodontic treatment received. The article also 
serves to emphasizes the importance of a multidisciplinary approach to TS patients.
CASE REPORT 
A Caucasian girl was referred at the age of 11 years and 1 month to a private offi ce 
for an orthodontic consultation. The primary complaint was protrusion of maxillary 
incisors. The patient reported that she had TS and that she had been on endocrine treatment 
for approximately 3 years, taking growth hormones (HGH, also known as somatropin) 
to stimulate her skeletal growth potential to its limit. She had a 45,X/46,XX mosaic 
karyotype and streak ovaries.
Extraoral examination revealed a relatively symmetrical face, normal lower anterior 
facial height, convex profi le with mandibular defi ciency, interlabial gap, nasobuccal 
airfl ow, and a habit of lip sucking (Figure 1).
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FIGURE 1 - Initial extraoral photos of the patient: A) profi le view; B) frontal view; and C) smiling frontal view.
The permanent dentition was analyzed by intraoral examination, fi nding central 
incisors exhibiting a typical cervico-incisal convergence of the proximal surfaces, with 
a biconvex “barrel” shape. There were also whitish spots of enamel hypoplasia on the 
incisal and occlusal edges of some dental elements, particularly on maxillary elements. 
The patient also exhibited 8 mm overjet and 80% overbite, maxillary atresia with ogival 
palate and Class II, Division 1 malocclusion, with maxillary diastemas and no midline 
deviation (Figure 2). 
FIGURE 2 - Initial intraoral photos of the patient: A) frontal; B) right lateral; C) left lateral; D) maxillary occlusal; 
and E) mandibular occlusal views.
Radiology did not reveal abnormal root morphology. Cephalometric analysis using 
profi le teleradiography showed skeletal Class II with mandibular retrusion and proclined 
maxillary incisors and mandibular incisors, well positioned in the jawbones. Carpal 
radiography revealed that the patient had entered the surge growth phase of puberty and 
so immediate facial orthopedic treatment was indicated (Figure 3).
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FIGURE 3 - Initial radiographs of the patient: A) panoramic; B) profi le teleradiography; and C) carpal.
Since the maxillary atresia would become more evident as a result of sagittal 
correction treatment, orthodontic planning included fi tting a Hyrax appliance to the 
upper arch. This appliance was also used to anchor a Herbst appliance for mandibular 
advancement (Figure 4). Interception with the Herbst appliance took 9 months and was 
followed by corrective orthodontic treatment lasting 16 months. 
FIGURE 4 - Herbst appliance after placement.
During periodic consultations for orthodontic maintenance, the patient was given 
guidance and supervision with regard to oral hygiene habits, such as proper use of 
toothbrush and fl uoride toothpaste and using dental fl oss for plaque control. 
After completion of the treatment, satisfactory results were observed with regard to 
dentofacial components (Figures 5 and 6). At the conclusion of orthodontic and endocrine 
therapy, the patient exhibited a positive somatic growth pattern, within the median curve 
on the growth chart (Figure 7).
FIGURE 5 - Final extraoral photos of the patient: A) profi le view; B) frontal view; and C) smiling frontal view.
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 FIGURE 6 - Final intraoral photos of the patient: A) frontal; B) right lateral; C) left lateral; D) maxillary occlusal; 
and E) mandibular occlusal views.
FIGURE 7 - Height and weight percentiles by age showing patient’s height of 115 cm relative to the growth curve at the 
age of eight and her height of 150 cm between the ages of 13 and 14, where it is within the average band for her age group. 
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DISCUSSION
It is extremely important that the treating health professional knows the natural 
history of TS, since ongoing management of the condition is basically centered on 
treating clinical manifestations. One of the strategies is hormonal treatment, which 
signifi cantly improves these patients’ quality of life. Nowadays this is the most 
recommended therapeutic approach (8,9). Although most patients do not exhibit 
hormone defi ciencies, treatment with HGH can help to normalize skeletal growth when 
properly administered (9,10). In this patient’s case, the hormone replacement therapy 
administered resulted in a satisfactory outcome, since the initial estimation had been 
a fi nal height far below the average population if she did not receive this treatment 
(Figure 7). This was of signifi cant relevance to treatment of the patient’s facial skeletal 
disharmony, since growth in body height is closely related to growth of the craniofacial 
structures (11). 
Over the last 50 years, HGH has been widely used to treat growth disorders. 
Usage has been increasing since 1960, when biosynthesis was achieved. Somatropin is 
the biosynthetic form of growth hormone and it signifi cantly increases patients’ growth 
speed and fi nal height (12,13).
The main predictive factor for the best possible response to growth hormone is the 
age of the patient when she starts treatment. Results are best when treatment is started 
early, at approximately 9 months of age. Patients who receive treatment early exhibit 
better results in terms of fi nal height (10,14-16). Studies that have assessed the long-term 
impact of HGH treatment show that patients have normal health status (17,18). In this 
case, the patient began hormonal replacement therapy at around the age of eight and, 
although it was started late, this treatment achieved a signifi cant improvement in the 
patient’s skeletal growth. If the therapy had been started earlier, the patient could possibly 
have exhibited even better results.
Only 10 to 12% of girls with TS secrete enough hormones to provoke spontaneous 
sexual development. Therefore, at the right time, replacement of estrogen to induce 
puberty is recommended for the majority of patients (19). Estrogen replacement therapy 
reduces the biological response to growth hormone, which is why the start of this therapy 
should be correctly timed in order to avoid drug interactions (20,21). Estrogen therapy is 
usually started when the girl is between 12 and 13 years old. The objective of treatment 
is development of secondary sexual characteristics and increase and maintenance of 
bone mass. Patients who do not receive replacement of these hormones may suffer from 
osteoporotic fractures (17-22). In this patient’s case, orthodontic treatment was concluded 
without the need for sexual hormone replacement, which may have contributed to the 
positive skeletal growth results achieved with orthopedic treatment. Nevertheless, 
endocrinological follow-up is a constant necessity, since a hormone insuffi ciency may 
arise at any point during the course of the patient’s life. 
There are no reports in the current literature of cases in which growth hormone has 
affected dental development and its infl uence is restricted to skeletal development (14). 
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Dental morphology studies show that the teeth of patients with TS exhibit reduced 
vestibule-palatal and mesiodistal dimensions. Incisors may display cervico-incisal 
convergence of proximal surfaces and have sharp edges, while canines can have sharp 
lingual cusps of regular size. Moreover, there are often atypical cusps and enamel tubercles 
on premolars and molars (23,24). Not all of these characteristics were observed in the 
case described here. Only the modifi ed morphology of maxillary incisors was seen, with 
the typical cervico-incisal convergence of proximal surfaces. Nonetheless, the skeletal 
pattern was as described in several reports found in the literature. 
Enamel hypoplasia is frequently observed in TS patients. This can be defi ned as an 
abnormality of the structure of the teeth causing quantitative and qualitative defects in 
which incomplete formation of the organic matrix of the teeth is the result of damage to 
ameloblasts (enamel-forming cells). In some of the cases reported in the literature there 
was total or partial absence of enamel, which was related to genetic infl uences on dental 
formation (24-26). In this clinical case, the patient exhibited hypoplasia, particularly of 
maxillary teeth, although this abnormality was not particularly severe. 
There are reports of cases of hyperplastic gingivitis, periodontal pockets, and dental 
mobility among adult patients (27). Gingival problems may be affected by hormone 
treatment, because an increase in systemic sexual hormones combined with dental 
plaque may result in periodontal diseases. This increase in levels of sexual hormones has 
been related to a strong gingival response to infl ammation, causing abnormal capillary 
permeability and greater accumulation of fl uid in gingival tissues, which results in edema, 
bleeding, and gingivitis when combined with dental plaque. Bleeding may occur during 
brushing and mastication (28). Due to such factors, the patient was encouraged to develop 
good oral hygiene habits, which were regularly supervised during monthly consultations, 
in order to avoid complications such as those described. Regular preventive maintenance 
should go beyond orthodontic follow-up, since both should happen simultaneously to 
prevent complications and promote oral health. 
It is imperative that girls and women with TS be treated by a multidisciplinary 
team that, in addition to the dental surgeon, includes a cardiologist, an endocrinologist, 
a geneticist and a professional to provide psychotherapeutic guidance (29).
The abnormalities of the buccal cavity that manifest with TS mean that the dental 
surgeon is one of the professionals whose work can improve TS patients’ quality of life. 
These patients require dental follow-up throughout their entire lives.
FINAL CONSIDERATIONS
The dental surgeon is one of the professionals whose work can improve the quality 
of life of patients with TS. Orthodontic and pediatric dental follow-up is fundamental to 
anticipate, prevent, and treat the most common oral complications. It can be concluded 
that when treated early by a multidisciplinary team, patients with TS may be able to live 
free from further complications and enjoy good quality of life.
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